SynthesisFrontiers in medicine2026
From histological recovery to residual gastric cancer risk after
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Successful Methods: Web of Science, Scopus, and PubMed were searched through 27 July 2026. Records were deterministically deduplicated and independently screened. Bibliometric networks, thematic structure, temporal bursts, and cited-reference relationships were analyzed. Two reviewers independently classified each publication into one of five mutually exclusive clinical decision domains. Temporal distributions were compared using Pearson's chi-square test, and a research-priority framework was synthesized by triangulating the quantitative findings with representative clinical evidence. Results: Of 778 source records, 283 publications from 1993 to 2026 were included. Reviewer agreement was 78.80% (Cohen's kappa = 0.722). Histological regression and mucosal recovery predominated in 1993-2007 (34.7%), whereas surveillance and prevention (39.6%) and risk stratification (30.2%) became dominant in 2008-2017 and remained the leading domains in 2018-2026. Domain distributions differed significantly across periods ( Conclusion: The field has shifted from asking whether gastric mucosal damage can recover to determining who remains at risk and how that risk should be managed. The resulting clinical decision taxonomy and research-priority framework support future validation of multimodal risk thresholds and comparative surveillance strategies; they do not establish universal surveillance or specific intervals.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.